Scynexis Secures $24.8M from GSK, Advances SCY-247 Pipeline
Event summary
- Scynexis received a $24.8M non-refundable payment from GSK in Q4 2025, extending its cash runway beyond two years.
- First patient dosed in Phase 1 study of IV formulation of SCY-247, with topline data expected in H2 2026.
- Expanded access program for SCY-247 planned for H1 2026 to address unmet needs in antifungal therapies.
- SCY-247 received QIDP and Fast Track designations from the FDA in January 2026.
The big picture
Scynexis's strategic focus on SCY-247 comes as the biotech sector faces increasing pressure to develop innovative solutions for drug-resistant infections. The $24.8M payment from GSK not only strengthens Scynexis's financial position but also underscores the potential of its proprietary fungerp platform. The company's ability to secure non-dilutive funding and navigate regulatory pathways will be critical in maintaining its competitive edge in the antifungal space.
What we're watching
- Clinical Progress
- The pace at which SCY-247 advances through Phase 1 and into Phase 2 studies will determine its viability as a next-generation antifungal.
- Financial Stability
- Whether Scynexis can sustain its cash runway beyond two years while advancing SCY-247 and exploring non-dilutive funding opportunities.
- Regulatory Dynamics
- How the FDA's QIDP and Fast Track designations will impact the development timeline and potential approval of SCY-247.
Related topics